ReviewFunctional foods and dietary supplements: Products at the interface between pharma and nutrition
Introduction
Since ancient times plants, herbs and other natural products have been used as healing agents. Advances in organic chemistry from the early 19th century have enabled the preparation of numerous synthetic medicines. Yet, the majority of the medicinal substances available today have their origin in natural compounds. The best known example is aspirin (acetylsalicylic acid), originally derived from the bark of the white willow tree (Leroux, 1830, Mahdi et al., 2006). Other examples include the immunosuppressive cyclosporines (Borel et al., 1990), the anthracycline antibiotics (Nadas and Sun, 2006) and the HMG-CoA reductase inhibitors, commonly known as statins (Endo, 2004).
Traditionally, pharmaceuticals have been used to cure diseases or to alleviate the symptoms of disease. Nutrition, on the other hand, is primarily aimed to prevent diseases by providing the body with the optimal balance of macro- and micronutrients needed for good health. Due to the emerging knowledge of disease, medicines are now increasingly being used to lower risk factors, and thereby to prevent chronic diseases. Prime examples are blood pressure lowering and blood lipid-lowering agents which reduce the risk of cardiovascular disease. The appearance of functional foods and dietary supplements on the market has further blurred the distinction between pharma and nutrition (Fig. 1). Functional foods are foods that are claimed to improve health, quality of life or well-being beyond basic nutritional functions (Henry, 2010, Howlett, 2008; ILSI Europe, 1999, van Kreijl et al., 2006). Examples of functional foods are margarines enriched with cholesterol-lowering phytosterols, cereals fortified with soluble fibres and yoghurts with specific bacterial cultures added. Thus, functional foods resemble conventional food products in appearance and are consumed as part of the usual diet. In contrast, dietary supplements are typically marketed in the form of a capsule, pill, powder or gel and are not presented for use as a conventional food, meal or diet. Dietary supplements contain one or more dietary ingredients (e.g., vitamins, minerals, amino acids, herbs or other botanicals) and are intended to supplement the diet (http://ods.od.nih.gov/) (U.S. Food and Drug Administration, 1994, van Kreijl et al., 2006).
Today's functional foods and dietary supplements are typically marketed to large (sub)groups of the total population. For example, phytosterol-enriched functional foods are targeted to all adults with (moderately) elevated cholesterol levels and products with claimed pre- and probiotic activity are aimed at general healthy populations. The recent advances in pharmaco- and nutrigenomics have formed the basis for developing the concepts of ‘personalized medicine’ (Personalized Medicine Coalition, 2009) and ‘personalized nutrition’ (Kaput, 2008, Kussmann and Fay, 2008). These emerging fields rely on targeted therapies based on a person's genetic risk profile. Pharmaceuticals (Caskey, 2010, Pravenec and Kurtz, 2007), as well as several dietary components (Afman and Müller, 2006), have been recognized to modulate gene and protein expression and thereby metabolic pathways, homeostatic regulation, and presumably health and disease. In addition, genes also contribute largely to different responses to diet or drug exposure, including interindividual variations in the occurrence of adverse drug reactions (Friso and Choi, 2002, Lee et al., 2010).
In the following sections we will first address the regulatory framework for drug and food safety and efficacy. In particular, we will focus on functional foods and dietary supplements, and the health claims related to these food products (2.1 Safety and efficacy of drugs, 2.2 Safety of food, 2.3 Efficacy of food: nutrition and health claims). Within the extensive regulatory framework, some (herbal) dietary supplements fall in between food and drug regulations, though (Section 2.4). Subsequently we describe the opportunities for functional foods and dietary supplements to reduce health risk factors and risk of diseases (Section 3.1), and discuss potential caveats of these food products (Section 3.2). Section 4 explains how health technology assessments, i.e. cost-effectiveness and risk-benefit analyses, can be used to make evidence-based decisions about which therapy, or combination of therapies, will result in the most successful and cost-effective management of health risk factors and chronic diseases. Finally, conclusions are drawn at the end of this paper (Section 5).
Section snippets
Safety and efficacy of drugs
An extensive legal regulatory system is in place for pharmaceutical products. Already shortly after the thalidomide affair in the 1960s, national and international regulatory authorities were established to monitor drug safety (Lisman and Lekkerkerker, 2005). Since 1995, the European Medicines Agency (EMA) is responsible for the scientific evaluation and monitoring of the safety and efficacy of pharmaceuticals in Europe (http://www.ema.europa.eu/ema/index.jsp?curl=/pages/home/Home_Page.jsp).
Opportunities of functional foods and dietary supplements
Functional foods or dietary supplements, i.e. those that carry substantiated health claims, can be helpful in reducing health risk factors and may thereby contribute to prevent chronic diseases. They are generally intended to be used by two categories of consumers. The first category comprises persons with modestly elevated risk factors who can take functional foods or dietary supplements as part of a healthy lifestyle, or to compensate for an unhealthy one. However, persons in this first
Health technology assessments of food and drugs
The aging of the population together with the rising health care costs underline the need to consider the cost-effectiveness of a treatment. It has been suggested that functional foods and dietary supplements, as part of healthy eating habits, can have a substantial effect on health care costs (Milner, 2000). Although cost-effectiveness assessments for pharmaceuticals are being used increasingly (Taylor et al., 2004), the cost-effectiveness of the use of functional foods or dietary supplements
Conclusion
Most chronic diseases of concern today are multifactorial in origin. For control, an approach in which medicines and nutrition are considered together and complement each other may result in the most successful and cost-effective management of health risk factors and chronic diseases. Functional foods and dietary supplements may become important players at the interface between pharma and nutrition, and merit attention from both a public health and a marketing perspective. The attention of the
References (101)
- et al.
Nutrigenomics: from molecular nutrition to prevention of disease
J. Am. Diet. Assoc.
(2006) - et al.
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up
Am. J. Cardiol.
(1994) Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment
Pharmacol. Res.
(2010)- et al.
European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety
Toxicology
(2006) - et al.
A general postlaunch monitoring framework for functional foods tested with the phytosterol/-stanol case
Trends Food Sci. Technol.
(2008) The origin of the statins. 2004
Atheroscler. Suppl.
(2004)- et al.
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice
Pharmacol. Res.
(2011) - et al.
Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols
Am. J. Med.
(2004) - et al.
Gene-nutrient interactions and DNA methylation
J. Nutr.
(2002) - et al.
The application of post-market monitoring to novel foods
Food Chem. Toxicol.
(2008)
Nutrigenomics research for personalized nutrition and medicine
Curr. Opin. Biotechnol.
Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels
Mayo Clin. Proc.
Functional foods: the US perspective
Am. J. Clin. Nutr.
Phytosterols and vascular disease
Atherosclerosis
Interaction between fibre and lovastatin
Lancet
Status of nutrition and health claims in Europe
Arch. Biochem. Biophys.
An update on drug interactions with the herbal medicine Ginkgo biloba
Curr. Drug Metab.
Advertising campaigns of sterol-enriched food. An often neglected cause of reduced compliance to lipid lowering drug therapy.
Cardiovasc. Drugs Ther.
ECJ 2009/02 Hecht-Pharma GmbH v. Staatliches Gewerbeaufsichtsamt Lüneburg and Vertreterin des Bundesinteresses beim Bundesverwaltungsgericht, 15 January 2009 (C-140/07)
Eur. J. Health Law
Vitamin K: a practical guide to the dietary management of patients on warfarin
Nutr. Rev.
Pharmacology of cyclosporine (sandimmune). I. Introduction.
Pharmacol. Rev.
Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations
AAPS J.
Decreased bioavailability of digoxin due to hypocholesterolemic interventions
Circulation
Combination therapy in the management of mixed dyslipidaemia
J. Intern. Med.
Using genetic diagnosis to determine individual therapeutic utility
Annu. Rev. Med.
Use of botanicals in food supplements. Regulatory scope, scientific risk assessment and claim substantiation
Ann. Nutr. Metab.
Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance
Eur. J. Clin. Nutr.
Functional foods: the case for closer evaluation
BMJ
Plant Sterols and Blood Cholesterol – Scientific substantiation of a health claim related to plant sterols and lower/reduced blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006
Plant stanol esters and blood cholesterol – Scientific substantiation of a health claim related to plant stanol esters and lower/reduced blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006
Xylitol chewing gum/pastilles and reduction of the risk of tooth decay – Scientific substantiation of a health claim related to xylitol chewing gum/pastilles and reduction the risk of tooth decay pursuant to Article 14 of Regulation (EC) No 1924/2006
ALA and LA and growth and development of children – Scientific substantiation of a health claim related to α-linolenic acid and linoleic acid and growth and development of children pursuant to Article 14 of Regulation (EC) No 1924/2006
Calcium and vitamin D and bone strength – Scientific substantiation of a health claim related to calcium and vitamin D and bone strength pursuant to Article 14 of Regulation (EC) No 1924/2006
Calcium and bone growth – Scientific substantiation of a health claim related to calcium and bone growth pursuant to Article 14 of Regulation (EC) No 1924/2006
Vitamin D and bone growth – Scientific substantiation of a health claim related to vitamin D and bone growth pursuant to Article 14 of Regulation (EC) No 1924/2006
Dairy fresh cheese and bone growth – Scientific substantiation of a health claim related to dairy fresh cheese and bone growth pursuant to Article 14 of Regulation (EC) No 1924/2006
Animal protein and bone growth – Scientific substantiation of a health claim related to animal protein and bone growth pursuant to Article 14 of Regulation (EC) No 1924/2006
Plant Stanols and Plant Sterols and Blood LDL-Cholesterol – Scientific Opinion on a request from the European Commission and a similar request from France in relation to the authorization procedure for health claims on plant stanols and plant sterols and lowering/reducing blood LDL-cholesterol pursuant to Article 14 of Regulation (EC) No 1924/2006
Danacol® and blood cholesterol Scientific substantiation of a health claim related to a low fat fermented milk product (Danacol®) enriched with plant sterols/stanols and lowering/reducing blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006
Scientific Opinion on the Substantiation of a health claim related to Iodine and the growth of children pursuant to Article 14 of Regulation (EC) No 1924/2006
Scientific Opinion on the Substantiation of a health claim related to Iron and cognitive development of children pursuant to Article 14 of Regulation (EC) No 1924/2006
Water-soluble tomato concentrate (WSTC I and II) and platelet aggregation [1]
Scientific Opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal blood pressure (ID 502), maintenance of normal HDLcholesterol concentrations (ID 515), maintenance of normal (fasting) blood concentrations of triglycerides (ID 517), maintenance of normal LDL-cholesterol concentrations (ID 528, 698) and maintenance of joints (ID 503, 505, 507, 511, 518, 524, 526, 535, 537) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
Guidance on human risk-benefit assessment of foods
Scientific Opinion on the modification of the authorisation of a health claim related to water-soluble tomato concentrate and helps to maintain a healthy blood flow and benefits circulation pursuant to Article 13(5) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of the Regulation (EC) No 1924/2006
Scientific Opinion in relation to the authorisation procedure for health claims on calcium and vitamin D and the reduction of the risk of osteoporotic fractures by reducing bone loss pursuant to Article 14 of Regulation (EC) No 1924/2006
Scientific concepts of functional foods in Europe. Consensus document.
Br. J. Nutr.
Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and novel food ingredients
White Paper on Food Safety - COM(1999) 719
Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs
Cited by (87)
Determination of caffeine in dietary supplements by miniaturized portable liquid chromatography
2022, Journal of Chromatography ADNA barcoding and metabarcoding for quality control of botanicals and derived herbal products
2022, Evidence-Based Validation of Herbal Medicine: Translational Research on BotanicalsFormulation and characterization of curcumin-loaded microemulsions: Evaluation of antioxidant stability and in vitro release
2021, Journal of Molecular LiquidsMental health of people with distorted body weight perception using medicinal remedies: A representative study
2021, International Journal of Clinical and Health PsychologyCitation Excerpt :Their responses were classified into four categories: “exercise,” “dietary,” “medical support (WCS-m),” and “never attempted” for examining their association with obesity-related psychological factors. Diet supplements category was broad and included traditional Chinese medicine, capsules, pills, and liquid, as well as other diet related supplements (Eussen et al., 2011). We considered diet supplements to be a part of the WCS-m category since the survey was conducted as a self-report.
- 1
P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Tel.: + 31 30 274 2387; fax: + 31 30 274 4466.